Abstract
Get full access to this article
View all access options for this article.
References
1.
Cooper
DS
,
Doherty
GM
,
Haugen
BR
,
Kloos
RT
,
Lee
SL
,
Mandel
SJ
,
Mazzaferri
EL
,
Mclver
B
,
Pacini
F
,
Schlumberger
M
,
Sherman
SI
,
Steward
DL
,
Tuttle
RM
. 2009 . Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer . Thyroid , 19 :1167 –1214 .
2.
Bal
CS
,
Kumar
A
,
Pant
GS
. 2004 . Radioiodine dose for remnant ablation in differentiated thyroid carcinoma: a randomized clinical trial in 509 patients . J Clin Endocrinol Metab , 89 :1666 –1673 .
3.
Hachshaw
A
,
Harmer
C
,
Mallick
U
,
Haq
M
,
Franklyn
JA
. 2007 . Review: I-131 activity for remnant ablation in patients with differentiated thyroid cancer: a systematic review . J Clin Endocrinol Metab , 92 :28 –38 .
4.
Maxon
HR
,
Thomas
SR
,
Hertzberg
VS
,
Kereiakes
JG
,
Chen
IW
,
Sperling
MI
,
Saenger
EL
. 1983 . Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer . N Engl J Med , 309 :937 –941 .